Vincenza Conteduca

Associate Professor

University of Foggia

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Cancer Biology Cancer Biology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Vincenza Conteduca is an Associate Professor at the University of Foggia, Italy. Her research focuses on the epidemiology of prostate cancer, particularly concerning biochemical recurrence and treatment outcomes, as well as the role of genetic factors in cancer therapy. She has contributed significantly to studies on renal cancer treatments and the implications of various signaling pathways in tumor biology. Her recent publications reflect her expertise in hematological toxicity associated with prostate cancer therapies and the importance of managing bone health in cancer patients.

Articles (17)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (15)

Maria Paola Costi

University of Modena and Reggio Emilia

ITALY

Vincenza Conteduca

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care

Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer Treatment

Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer?

Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies.

Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study.

Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer

TRAP1 modulates mitochondrial biogenesis via PGC-1α/TFAM signalling pathway in colorectal cancer cells

Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients

Correction to: Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis (Targeted Oncology, (2024), 19, 1, (1-11), 10.1007/s11523-023-01016-x)

Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis

Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma

Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review

Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer

Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy

Collaborators (15)

Maria Paola Costi

Fulvio Magni

Isabella Piga

Emanuela Scarpi

giuseppe schepisi

Marco Villani

Emilio Francesco Giunta

Pasquale Rescigno

Sara Bleve

Clizia Chinello

Matteo Landriscina

Marco Stellato

Nicole Brighi

Alberto Martini

Domenico D’Arca

Make your next move.